Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vertex Pharmaceuticals Incorporated (VRTX)

225.55   -0.57 (-0.25%) 01-17 16:53
Open: 226.59 Pre. Close: 226.12
High: 227.44 Low: 224.46
Volume: 2,242,187 Market Cap: 58,652M
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 228.925 - 231.122 231.122 - 232.451
Low: 219.717 - 222.635 222.635 - 224.399
Close: 222.228 - 226.945 226.945 - 229.797

Technical analysis

as of: 2021-01-15 4:46:49 PM
Overall:       
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 271.60     One year: 279.98
Support: Support1: 220.93    Support2: 183.81
Resistance: Resistance1: 232.54    Resistance2: 239.71
Pivot: 231.12
Moving Average: MA(5): 228.56     MA(20): 232.29
MA(100): 239.48     MA(250): 251.88
MACD: MACD(12,26): -0.16     Signal(9): 0.94
Stochastic oscillator: %K(14,3): 24.40     %D(3): 34.82
RSI: RSI(14): 43.54
52-week: High: 306.08  Low: 197.47  Change(%): -3.6
Average Vol(K): 3-Month: 187166  10-Days: 185270

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
VRTX has closed above bottom band by 12.1%. Bollinger Bands are 49.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to VRTX's normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 15 Jan 2021
Vertex Pharmaceuticals (VRTX) Stock Moves -0.25%: What You Should Know - Nasdaq

Thu, 14 Jan 2021
Vertex Pharmaceuticals Incorporated (VRTX) Stock: How Does it Score on Fundamental Metrics? - InvestorsObserver

Mon, 11 Jan 2021
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript) - Seeking Alpha

Mon, 11 Jan 2021
Vertex Pharmaceuticals To Present At The J.P. Morgan Healthcare Conference; Webcast At 9:10 AM ET - Nasdaq

Fri, 08 Jan 2021
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Nasdaq

Thu, 07 Jan 2021
Vertex Pharmaceuticals (NASDAQ:VRTX) Cut to "Sell" at BidaskClub - MarketBeat

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 260
Shares Float (M) 260
% Held by Insiders 0.09
% Held by Institutions 95.68
Shares Short (K) 3,250
Shares Short P. Month (K) 2,750

Stock Financials

EPS 10.200
EPS Est This Year 1.630
EPS Est Next Year 2.890
Book Value (p.s.) 31.260
Profit Margin 44.91
Operating Margin 44.67
Return on Assets (ttm) 17.8
Return on Equity (ttm) 40.2
Qtrly Rev. Growth 62.0
Gross Profit (p.s.) 7.153
Sales Per Share 23.035
EBITDA (p.s.) 10.691
Qtrly Earnings Growth 1060.40
Operating Cash Flow (M) 3,210
Levered Free Cash Flow (M) 2,070

Stock Valuations

PE Ratio 22.11
PEG Ratio 0.36
Price to Book value 7.22
Price to Sales 9.79
Price to Cash Flow 18.27

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.